Although some patients with stage II/III colorectal cancer were at an increased risk of severe symptoms and deterioration over time, patient-reported symptoms showed that those with newly diagnosed disease generally reported a low symptom burden that remained stable or improved after receiving adjuvant systemic therapy, according to a retrospective analysis.
Read More
HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain
March 21st 2023Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.
Read More
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
March 11th 2023Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.
Read More
Pilewskie Highlights Trends for Surgical Management of High-risk Breast Lesions
March 3rd 2023Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®
Read More
Ide-Cel Is Effective, Safe for Patients With R/R Multiple Myeloma and Renal Insufficiency
February 17th 2023Patients with relapsed or refractory multiple myeloma treated with the CAR T-cell agent idecabtagene vicleucel had comparable efficacy and safety outcomes regardless of whether they had renal impairment, according to findings from a real-world study.
Read More
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
February 6th 2023As more agents are evaluated either in addition to or following PD-1/PD-L1 inhibitors, more information may be learned about how best to leverage alternate biomarkers, according to Marina C. Garassino, MD.
Read More
Early Exploration With HER-Vaxx Extends Survival for Patients with HER2+ Gastric/GEJ Adenocarcinoma
January 20th 2023Patients with HER2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma treated with HER-Vaxx plus standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone.
Read More
Neoadjuvant Nivolumab Plus Chemotherapy Bests Nivolumab Alone in Resectable NSCLC
December 9th 2022Neoadjuvant treatment with nivolumab (Opdivo) plus platinum doublet chemotherapy showed superior major pathological response rates and pathological complete response rates compared with nivolumab monotherapy among patients with resectable non–small cell lung cancer even for patients with a PD-L1 expression of 50% or greater.
Read More
Multidisciplinary Workflow Benefits Patients With Newly Diagnosed Pancreatic Cancer
November 15th 2022Early experience with a newly designed pancreatic cancer multidisciplinary clinic workflow at Roswell Park Comprehensive Cancer Center in Buffalo, New York, showed significant improvement in terms of time to subspecialty evaluation.
Read More
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
November 14th 2022In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.
Read More
PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer
November 10th 2022The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.
Read More
Frontline Setting Boasts Multiple Treatment Options for Patients With ALL
November 9th 2022Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.
Read More